Comparative study of cisplatin plus gemcitabine versus cisplatin plus vinorelbine in patients with advanced stage non-small cell lung cancer
- VernacularTitle:顺铂加吉西他滨与顺铂加长春瑞滨一线治疗晚期非小细胞肺癌的对照研究
- Author:
Wenying ZHAO
;
Zhaoning JI
- Publication Type:Journal Article
- Keywords:
non-small cell lung cancer;
chemotherapy;
gemcitabine;
vinorelbine;
cisplatin
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2004;0(12):-
- CountryChina
- Language:Chinese
-
Abstract:
AIM: To explore the differences of efficacy and side-effects in advanced stage non-small cell lung cancer (NSCLC) patients treated with gemcitabine plus cisplatin or vinorelbine plus cisplatin. METHODS: Eligible patients were randomly assigned to GP (gemcitabine+cisplatin) group or NP (vinorelbine plus cisplatin) group. In GP group, 36 evaluable patients were treated with gemcitabine 1000 mg?m~ -2 IV on day 1 and 8 and cisplatin 75 mg?m~ -2 IV which was divided into 1-3 days dosing, in a 21 days per cycle manner. In NP group, 30 evaluable patients were treated with vinorelbine 25 mg?m~ -2 IV on day 1 and 8 and cisplatin 80 mg?m~ -2 IV which was divided into 1-3 days dosing, 21 days per cycle. All the patients at least received two cycles therapy. The response rate, median survival time (MST), l year survival, and side-effects were observed. RESULTS: The response rates were 41.6 % vs 36.7 %; MST were 10.3 months vs 9.6 months; 1 year survival rate were 44.4 % vs 40.0 %(P= 0.33 ) in GP group and NP group, respectively. III-IV grade thrombocytopenia toxicity incurred significantly higher in GP group than in NP group, with the occurrence rate being 47.2 % vs 6.6 % (P
